Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Disorders of the Urinary System01:20

Disorders of the Urinary System

The urinary system is responsible for eliminating waste and excess fluids from the body. However, disorders of the urinary system can arise due to various reasons like infections, stress, age, congenital abnormalities, and lifestyle.
Urinary tract infections (UTIs) are one of the most common urinary system disorders. They are caused by bacteria that enter the urethra and can spread to the bladder resulting in cystitis. Pyelonephritis is the result of a UTI that has ascended to the level of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Urinary disturbances in parkinsonism].

Ugeskrift for laeger·2025
Same author

Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns.

Journal of neuroinflammation·2024
Same author

Identifying the prevalence of Parkinson's disease in Denmark using healthcare registries and self-reported survey data.

Parkinsonism & related disorders·2024
Same author

Clinical Markers of 6 Pre-dominant Coping Behaviors in Living With Parkinson Disease: A Convergent Mixed Methods Study.

Inquiry : a journal of medical care organization, provision and financing·2022
Same author

Brain proteome profiling implicates the complement and coagulation cascade in multiple system atrophy brain pathology.

Cellular and molecular life sciences : CMLS·2022
Same author

Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.

Parkinsonism & related disorders·2021

Related Experiment Video

Updated: May 23, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

Bladder dysfunction in advanced Parkinson's disease.

Kristian Winge1, Kurt K Nielsen

  • 1Copenhagen Movement Disorders Centre, Bispebjerg Hospital, Copenhagen, Denmark. k.winge@dadlnet.dk

Neurourology and Urodynamics
|April 11, 2012
PubMed
Summary

Lower urinary tract symptoms (LUTS) are common in advanced Parkinson's disease (PD). While treatments like deep-brain stimulation (DBS) didn't alter overall LUTS severity, they significantly reduced nocturia in PD patients.

More Related Videos

Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

Related Experiment Videos

Last Updated: May 23, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

Area of Science:

  • Neurology
  • Urology
  • Movement Disorders

Background:

  • Lower urinary tract symptoms (LUTS) are prevalent in Parkinson's disease (PD), affecting up to 74% of patients.
  • Severe bladder dysfunction is reported in 27-39% of individuals with PD.

Purpose of the Study:

  • To evaluate the severity of bladder dysfunction in patients with advanced Parkinson's disease.
  • To compare LUTS across different treatment modalities for advanced PD.

Main Methods:

  • 107 patients with advanced PD were assessed using the Danish Prostate Symptom Score (DanPSS) and International Prostate Symptom Score (IPSS).
  • Patients were categorized into groups receiving oral medications, deep-brain stimulation (DBS) in the subthalamic nucleus, or apomorphine pump therapy.
  • Postmicturitional residual urine volume was measured.

Main Results:

  • No statistically significant differences in overall bladder symptom scores (DanPSS, IPSS) were observed between treatment groups.
  • Bladder symptom severity correlated with disease stage in conventionally treated and apomorphine groups, and with DBS duration in the DBS group.
  • Patients treated with DBS experienced significantly less nocturia compared to oral medication or apomorphine pump groups.

Conclusions:

  • LUTS are highly prevalent in advanced PD, with over 50% experiencing severe symptoms, often overactive bladder.
  • Deep-brain stimulation (DBS) in the subthalamic nucleus did not alter overall LUTS severity compared to oral or apomorphine treatments.
  • DBS treatment was associated with a significant reduction in nocturia among advanced PD patients.